APA

Josephs K. A., Whitwell J. L., Knopman D. S., Hu W. T., Stroh D. A., Baker M., Rademakers R., Boeve B. F., Parisi J. E., Smith G. E., Ivnik R. J., Petersen R. C., Jack C. R. & Dickson D. W. (20080606). Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. : Neurology.

Chicago

Josephs K A, Whitwell J L, Knopman D S, Hu W T, Stroh D A, Baker M, Rademakers R, Boeve B F, Parisi J E, Smith G E, Ivnik R J, Petersen R C, Jack C R and Dickson D W. 20080606. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. : Neurology.

Harvard

Josephs K. A., Whitwell J. L., Knopman D. S., Hu W. T., Stroh D. A., Baker M., Rademakers R., Boeve B. F., Parisi J. E., Smith G. E., Ivnik R. J., Petersen R. C., Jack C. R. and Dickson D. W. (20080606). Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. : Neurology.

MLA

Josephs K A, Whitwell J L, Knopman D S, Hu W T, Stroh D A, Baker M, Rademakers R, Boeve B F, Parisi J E, Smith G E, Ivnik R J, Petersen R C, Jack C R and Dickson D W. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. : Neurology. 20080606.